Koen A Marijt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9286291/publications.pdf

Version: 2024-02-01

		840776	1058476
17	1,116	11	14
papers	citations	h-index	g-index
17	17	17	2495
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4470-4475.	7.1	251
2	NKG2A Blockade Potentiates CD8ÂT Cell Immunity Induced by Cancer Vaccines. Cell, 2018, 175, 1744-1755.e15.	28.9	241
3	Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy. Nature Medicine, 2019, 25, 612-619.	30.7	156
4	PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy. Oncolmmunology, 2017, 6, e1294299.	4.6	114
5	Identification of non-mutated neoantigens presented by TAP-deficient tumors. Journal of Experimental Medicine, 2018, 215, 2325-2337.	8.5	64
6	Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFN \hat{I}^3 receptor signaling. , 2019, 7, 152.		57
7	Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer. Endocrine-Related Cancer, 2016, 23, 35-45.	3.1	49
8	Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity. Nature Communications, 2019, 10, 3773.	12.8	47
9	TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class llow cancers. Molecular Immunology, 2019, 113, 43-49.	2.2	36
10	Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model., 2020, 8, e000772.		36
11	T cells specific for a TAP-independent self-peptide remain na \tilde{A}^- ve in tumor-bearing mice and are fully exploitable for therapy. Oncolmmunology, 2018, 7, e1382793.	4.6	18
12	To TAP or not to TAP: alternative peptides for immunotherapy of cancer. Current Opinion in Immunology, 2020, 64, 15-19.	5.5	16
13	Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors. Cancer Immunology Research, 2020, 8, 856-868.	3.4	12
14	TEIPP peptides: exploration of unTAPped cancer antigens. Oncolmmunology, 2019, 8, 1599639.	4.6	8
15	Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement. Cancer Immunology, Immunotherapy, 2021, , 1.	4.2	5
16	Association of cognitive function with increased risk of cancer death and all-cause mortality: Longitudinal analysis, systematic review, and meta-analysis of prospective observational studies. PLoS ONE, 2022, 17, e0261826.	2.5	5
17	Abstract LB-346: Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. , 2016, , .		1